Ghrp-2 10mg 1kits (10Vials)

Ō¢ÄGHRP-2 Structure  

Source: PubChem

Sequence: AXAWFK Molecular Formula: C45H55N9O6 Molecular Weight: 817.98 g/mol CAS Number:158861-67-7 PubChem CID’╝Ü6918245 Synonyms: Pralmorelin’╝øpralmorelina’╝øKP-102’╝øpralmoreline

 

Ō¢ÄGHRP-2 Research

What is the research background of GHRP-2? Growth hormone plays a pivotal role in human growth, development, and metabolic balance. Scientists have long sought substances capable of effectively regulating its secretion. Growth hormone-releasing peptides (GHRPs), a class of synthetic oligopeptides that stimulate growth hormone release, have emerged as a focus of research. GHRP-2 mimics the action of ghrelin by binding to the ghrelin receptor, activating signaling pathways to efficiently stimulate GH release. It demonstrates potential in diagnosing and treating growth hormone deficiency, intervening in anorexia, and protecting against organ damage, driving deeper research into its mechanisms and applications.   What is the mechanism of action for GHRP-2? Regulation of Growth Hormone Secretion Acting on the Hypothalamic-Pituitary Axis: GHRP-2 stimulates growth hormone (GH) release through a unique dual-complementary action targeting both the hypothalamus and pituitary gland (Bowers C Y). At the pituitary level, GHRP-2 binds to the growth hormone-releasing hormone receptor (GHS-R). Upon binding to GHS-R, GHRP-2 initiates a cascade of intracellular signaling events. For instance, it activates phospholipase C (PLC), which catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) on the cell membrane into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 promotes calcium ion release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC), ultimately leading to GH release (Roh S G,). In a study using bovine pituitary cells, GHRP-2 at various concentrations (10Ōü╗ŌŖā1;ŌŖā3; to 10Ōü╗ŌüĘ M) significantly increased GH secretion (P < 0.05), indicating a direct stimulatory effect of GHRP-2 on GH secretion by pituitary cells ^[1]. Synergistic Action with Growth Hormone-Releasing Hormone (GHRH): GHRP-2 exhibits synergistic effects with GHRH in stimulating GH release. When co-administered to pituitary cells, they act through distinct signaling pathways that ultimately converge to promote GH secretion. Studies indicate that GHRH primarily activates adenylate cyclase (AC), elevating intracellular cAMP levels to subsequently activate protein kinase A (PKA), thereby promoting GH gene transcription and GH synthesis/release. Conversely, GHRP-2 exerts its effects via the PLC-IP3/DAG-PKC pathway described above. Their synergistic interaction significantly increases GH release. In sheep pituitary cell experiments, both GHRH (10 nM) and GHRP-2 (100 nM) individually increased GH mRNA levels and GH release in a time-dependent manner within 0.5ŌĆō2 hours; this effect was markedly enhanced when combined ^[2]. Regulation of Growth Hormone Secretion: GHRP-2 stimulates growth hormone (GH) release through a unique dual-complementary action, simultaneously targeting the hypothalamus and pituitary gland (Bowers CY). At the pituitary level, GHRP-2 binds to the growth hormone-releasing hormone receptor (GHS-R). Upon binding to GHS-R, GHRP-2 initiates a cascade of intracellular signaling events. For instance, it activates phospholipase C (PLC), which catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) on the cell membrane into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 promotes calcium ion release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC), ultimately leading to GH release (Roh S G,). In a study using bovine pituitary cells, GHRP-2 at various concentrations (10Ōü╗ŌŖā1;ŌŖā3; to 10Ōü╗ŌüĘ M) significantly increased GH secretion (P < 0.05), indicating a direct stimulatory effect of GHRP-2 on GH secretion by pituitary cells ^[1]. Therapeutic Effects on Anorexia: For patients with anorexia, intranasal administration of GHRP-2 increases hunger sensation and food intake, reduces early satiety, and improves hypoglycemia symptoms. After 14 months of GHRP-2 administration, patients gradually gained 6.7 kg in body weight. The mechanism may involve GHRP-2 acting as a ghrelin receptor agonist to mimic ghrelin's effects, thereby modulating the appetite center and improving patients' eating behavior and nutritional status ^[3]. Figure 1 (A) Changes in body weight, muscle mass, and fat mass after treatment with growth hormone releasing peptide-2 (GHRP-2). Fat and muscle mass were evaluated using the bio-impedance method. All parameters gradually increased, with body weight and daily energy intake rising by ŌłÆ1.5 to 2.4 kg and 12% to 36%, respectively, after ghrelin infusion. (B) Changes in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels following GHRP-2 treatment. GH decreased while IGF-1 increased after 12 months. (C) Changes in nutritional status. Retinol binding protein (RBP) and total protein (TP) rose rapidly, with albumin (Alb) increasing after 4 months. These parameters further increased after 12 months. (D) Changes in acyl ghrelin (AG) and des-acyl ghrelin (DAG) levels after GHRP-2 administration. Fasting DAG and AG increased, and the DAG/AG ratio decreased after 10 months. BW; body weight. Source: PubMed ^[3]   What are the medical applications of GHRP-2? Diagnosis of growth hormone secretion deficiency: GHRP-2 is clinically used as a diagnostic agent for growth hormone deficiency. For adult growth hormone deficiency, the international first-line diagnostic test is the insulin tolerance test (ITT). However, due to its potential to cause serious adverse events, it is contraindicated for some patients. Studies have proposed using GHRP-2 to diagnose adult growth hormone deficiency (GHD). The study enrolled 77 healthy subjects and 58 patients with peak GH < 3 ╬╝g/L as determined by ITT. All subjects received an intravenous injection of 100 ╬╝g GHRP-2, followed by blood sampling over the subsequent 2 hours. GH levels were measured using an immunoradiometric assay. Results showed that all subjects exhibited peak serum GH within 60 minutes post-GHRP-2 administration. GH responsiveness to GHRP-2 was unaffected by gender. Although responses were slightly lower in elderly subjects and obese individuals, this did not compromise GHD diagnosis. Repeat testing demonstrated good reproducibility of this method. When using GHRP-2 to diagnose GHD, a cutoff value of 15 ╬╝g/L corresponds to the diagnostic value of 3 ╬╝g/L in the ITT, indicating that setting an appropriate serum GH concentration cutoff reliably diagnoses severe growth hormone deficiency ^[4]. Treatment of Anorexia: For patients with a long history of anorexia, GHRP-2 may represent a promising therapeutic agent. One study administered GHRP-2 intranasally before each meal for one year to a patient with a 20-year history of anorexia. Prior to treatment, although the patient's fear of eating and desire to be thin had diminished through previous therapies, gastrointestinal dysfunction prevented increased food intake and weight gain. Symptoms included postprandial vomiting, constipation, sub-intestinal obstruction, and hypoglycemia. Following GHRP-2 administration, the patient experienced increased hunger and food intake, reduced early satiety, hypoglycemia symptoms improved, and body weight gradually increased by 6.7 kg (from 21.1 kg to 27.8 kg) within 14 months of initiating treatment. Fatigue and muscle strength improved, physical and mental activity increased, and no significant side effects were observed with long-term intranasal administration. This suggests GHRP-2 may be an effective therapeutic agent for patients with severe chronic anorexia ^[3]. Alleviating Burn-Induced Dysfunction: Following severe burns, increased production of catabolic hormones and inflammatory cytokines alongside decreased anabolic hormone levels leads to metabolic hyperactivity, reduced lean body mass, and muscle wasting. Although various therapies such as exercise and the use of anabolic hormones (insulin, growth hormone, IGF-I, or steroids) have been proposed or employed, their effects remain suboptimal. Experimental results indicate that the newly isolated anti-cachexia peptide ghrelin is downregulated in post-burn rats. Exogenous ghrelin can restore weight loss by increasing food intake and enhancing muscle mass in mice. It also significantly reduces skeletal muscle protein degradation in burn rats by normalizing muscle mRNA expression of E3 ubiquitin ligase, MuRF1, and MAFbx. The short half-life of ghrelin limits its clinical application. In contrast, the synthetic hexapeptide growth hormone-releasing peptide 2 (GHRP-2) is a stable and potent GHRP receptor agonist that increases body weight in rodents, exhibits anti-inflammatory effects in arthritic rats, and improves catabolic metabolism in critically ill patients. GHRP-2 positively influences body weight, food intake, and skeletal muscle protein breakdown in burned rodents, mitigating burn-induced dysfunction [5].   Conclusion GHRP-2 activates growth hormone secretion by stimulating relevant signaling pathways through its action on GHS-R within the hypothalamic-pituitary axis. Medically, it can diagnose growth hormone deficiency and treat conditions such as anorexia, septic acute kidney injury, and post-burn dysfunction, while also exhibiting analgesic and antioxidant effects.   About The Author The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.   Scientific Journal Author Haruta I is a clinician-scientist affiliated with the Department of Psychosomatic Internal Medicine at Kagoshima UniversityŌĆÖs Graduate School of Medical and Dental Sciences in Japan. Her translational research focuses on endocrine and metabolic interventions in severe anorexia nervosa. Haruta I is listed in the reference of citation [3].

Ō¢ÄRelevant Citations

  [1] Roh SG, He ML, Matsunaga N, Hidaka S, Hidari H. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary  cells. Journal of Animal Science 1997; 75(10): 2744-2748.DOI: 10.2527/1997.75102744x.   [2] Yan M, Hernandez M, Xu R, Chen C. Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH,  pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and  somatostatin receptor mRNAs in ovine pituitary cells. European Journal of Endocrinology 2004; 150(2): 235-242.DOI: 10.1530/eje.0.1500235.   [3] Haruta I, Fuku Y, Kinoshita K, et al. One-year intranasal application of growth hormone releasing peptide-2 improves  body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. Journal of Cachexia Sarcopenia and Muscle 2015; 6(3): 237-241.DOI: 10.1002/jcsm.12028.   [4] Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. European Journal of Endocrinology 2007; 157(1): 19-27.DOI: 10.1530/EJE-07-0066.   [5] Balasubramaniam A, Joshi R, Friend LA, James JH. GHRP-2 attenuates burn-induced dysfunctions in rodents. Advances in Experimental Medicine and Biology 2009; 611: 571-572.DOI: 10.1007/978-0-387-73657-0_251.  

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

 

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.